Advertising
Showing 1 to 14 of 14 entries
  • «
  • 1
  • »
COMMENT
Part of their trial was suspended. Some of the patients had above normal liver enzymes. However, other arms are proceeding. The findings will show whether it has less liver toxicity. Have enough cash to go on for 2.5 more years.
Pharma & Healthcare
BUY
Disclosure: he recently participated in their latest round of financing. They produce a pain medication to treat gut problems. They're now testing the drug or will very soon. They've done phase 2, a risky phase. He expects big pharma partners to help them in phase 3, which will take a year and a half plus a lot of money roughly. There's a potential US$11 billion market, so the pay off can be huge backed by strong, desperate demand. They have other drugs in the pipeline, too.
Pharma & Healthcare
PAST TOP PICK
(A Top Pick Aug 01/19, Up 24%) There's been a lot going here: the reported good phase 2 drug test results. They did financing recently and are planning for phase 3 which will cost $50 million, so they have enough cash for 18 months. The next phase will start in Q2 2021 and last two years. Generally, drugs that pass phase 2 have a good outlook entering phase 3. ATE continues to talk to third parties about mass-producing the drug.
Pharma & Healthcare
BUY
One of the Top Picks he made at $0.42 previously. A pain medication that does not burn a hole in your stomach. They have completed a test of over 300 patients in Canada that is expected by end-June. If successful, the stock should be trading north of $1. He owns over 200,000 shares.
Pharma & Healthcare
STRONG BUY
Hydrogen Sulfide Coated Naproxen so it won't cut a hole in your gut. It is in testing. It is expected about Apr 17th they should announce the results of testing. It is a real bargain here.
Pharma & Healthcare
HOLD
They develop non-addictive pain medication drugs through the trial process. They trade at 17 times trailing sales -- a bit expensive. He thinks they are about to go into a good revenue growth phase. He would be a hold at this valuation. A slip up at this point could lead to a sizable pullback. The risks are heightened here.
Pharma & Healthcare
BUY
They have a pain medication that does not aggravate the stomach. Testing on a new product should be done by March (reported in May), which should result in a new product in a $11 billion market in the US. He owns it personally.
Pharma & Healthcare
BUY
Still trending up to 60 cents. There's runway ahead. Moving averages point higher.
Pharma & Healthcare
COMMENT
He owns quite a lot of this stock. They haven’t seen any notification of them finishing recruitment for their study subjects. Regardless, he is very positive on the stock for their pain medicine. The results of the study are soon to be released.
Pharma & Healthcare
BUY
It makes a competitive drug for creaky knees and arthritis but the current drug they are competing against will burn a whole in your stomach if you take it for more than two weeks. The current study should be out by mid-December. There seems to be another 3 times upside in the stock price. This is one of three powerful drugs they have.
Pharma & Healthcare
BUY
He thinks there is lots more upside yet to come. They have an NSAID that does not drill a hole in your stomach. He thinks an NSAID manufacturer would likely buy them out.
Pharma & Healthcare
TOP PICK
Market cap of $69 million. Pain medications create stomach upset. They produce a coating to counteract that. They are also working on a non-steroid anti-inflammatory drug in the US. They are testing it on over 350 patients in 35 different facilities. This would put them into an $11 billion US market if successful. The results are expected in end-September. There is a 5 times upside potential here. A speculative buy. Yield 0% (Analysts’ price target is $1.45)
Pharma & Healthcare
WATCH
Their latest drug is undergoing tests do and is so far doing well. He expects the next results in Q3. The drug could be a $1 billion/year sales opportunity. ATE will partner with a global pharmaceutical. Watch those results.
Pharma & Healthcare
BUY
Instead of using existing NSAIDs for arthritis and getting holes in your stomach, their drug is coated with sulfur and it is effective, even in lower doses. Phase II studies should be completed by end of year or there may even be news by end of June. He thinks it is a very sound science.
Pharma & Healthcare
Showing 1 to 14 of 14 entries
  • «
  • 1
  • »

Antibe Therapeutics Inc.(ATE-X) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Antibe Therapeutics Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Antibe Therapeutics Inc.(ATE-X) Frequently Asked Questions

What is Antibe Therapeutics Inc. stock symbol?

Antibe Therapeutics Inc. is a OTC stock, trading under the symbol ATE-X on the (). It is usually referred to as or ATE-X

Is Antibe Therapeutics Inc. a buy or a sell?

In the last year, 1 stock analyst published opinions about ATE-X. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Antibe Therapeutics Inc..

Is Antibe Therapeutics Inc. a good investment or a top pick?

Antibe Therapeutics Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Antibe Therapeutics Inc..

Why is Antibe Therapeutics Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Antibe Therapeutics Inc. worth watching?

1 stock analyst on Stockchase covered Antibe Therapeutics Inc. In the last year. It is a trending stock that is worth watching.

What is Antibe Therapeutics Inc. stock price?

On , Antibe Therapeutics Inc. (ATE-X) stock closed at a price of $.